FPHAX Holdings — Select Pharmaceuticals Portfolio
Data updated: 2026-07-24
FPHAX holds 57 securities. The top 10 make up 73.8% of net assets, led by ELI LILLY and (28.78%) and Gsk PLC Spons ADR (8.17%). Health Care (97.0%) and Funds & ETFs (2.6%) are the largest sectors, and 64.8% of the portfolio is in United States. Debt holdings: 1 position, under 0.1% of assets.
Holdings cover 102.05% of net asset value (99.55% of total assets; remainder is cash and receivables). As of May 31, 2026 · N-PORT.
FPHAX Portfolio Holdings
57 holdings of Select Pharmaceuticals Portfolio by percentage of net assets, from the fund's SEC N-PORT filing as of May 31, 2026.
| Holding | Ticker | Sector | % of net assets | Value (USD) |
|---|---|---|---|---|
| ELI LILLY and CO | LLY | Health Care | 28.78% | $431.84M |
| Gsk PLC Spons ADR | GSK | Health Care | 8.17% | $122.57M |
| Viatris, Inc. | VTRS | Health Care | 5.45% | $81.83M |
| Ucb SA | — | Health Care | 5.09% | $76.36M |
| MERCK and CO INC NEW | MRK | Health Care | 4.74% | $71.15M |
| Roche Holding AG | — | Health Care | 4.54% | $68.19M |
| Legend Biotech Corp. Spon ADR | LEGN | Health Care | 4.53% | $68.02M |
| Astrazeneca PLC | AZN | Health Care | 4.22% | $63.38M |
| Elanco Animal Health, Inc. | ELAN | Health Care | 4.15% | $62.27M |
| Jazz Pharma PLC | JAZZ | Health Care | 4.09% | $61.39M |
| Gilead Sciences, Inc. | GILD | Health Care | 3.97% | $59.53M |
| JOHNSON and JOHNSON | JNJ | Health Care | 3.77% | $56.60M |
| Royalty Pharma PLC | RPRX | Health Care | 2.67% | $40.09M |
| Fidelity Securities Lending Cash Central Fund | — | Funds & ETFs | 2.44% | $36.65M |
| Moderna, Inc. | MRNA | Health Care | 1.57% | $23.56M |
| Intellia Therapeutics, Inc. | NTLA | Health Care | 1.19% | $17.82M |
| Beam Therapeutics, Inc. | BEAM | Health Care | 1.10% | $16.48M |
| Axsome Therapeutics, Inc. | AXSM | Health Care | 1.08% | $16.18M |
| Biontech SE ADR | BNTX | Health Care | 1.04% | $15.66M |
| Xenon Pharmaceuticals, Inc. | XENE | Health Care | 0.82% | $12.37M |
| Ocular Therapeutix, Inc. | OCUL | Health Care | 0.80% | $12.00M |
| Idexx Labs, Inc. | IDXX | Health Care | 0.61% | $9.13M |
| Swedish Orphan Biovitrum Ab | — | Health Care | 0.54% | $8.15M |
| Ptc Therapeutics, Inc. | PTCT | Health Care | 0.54% | $8.12M |
| Capricor Therapeutics, Inc. | CAPR | Health Care | 0.46% | $6.93M |
| Kymera Therapeutics, Inc. | KYMR | Health Care | 0.46% | $6.88M |
| Raia Drogasil SA | — | Consumer Staples | 0.42% | $6.27M |
| Annexon, Inc. | ANNX | Health Care | 0.36% | $5.44M |
| Arrowhead Pharmaceuticals, Inc. | ARWR | Health Care | 0.34% | $5.10M |
| Harmony Biosciences Holdings, Inc. | HRMY | Health Care | 0.33% | $5.01M |
| Serif Biomedicines, Inc. Pc Pp | — | Health Care | 0.33% | $5.00M |
| Crinetics Pharmaceuticals, Inc. | CRNX | Health Care | 0.31% | $4.67M |
| Definium Therapeutics, Inc. | DFTX | Health Care | 0.30% | $4.55M |
| Corcept Therapeutics, Inc. | CORT | Health Care | 0.29% | $4.33M |
| Uniqure N.v. | QURE | Health Care | 0.28% | $4.20M |
| Ascendis Pharma As | ASND | Health Care | 0.27% | $4.10M |
| Agomab Therapeutics SA (180 Day Lock-Up) | — | Health Care | 0.25% | $3.74M |
| Disc Medicine, Inc. | IRON | Health Care | 0.25% | $3.74M |
| Amylyx Pharmaceuticals, Inc. | AMLX | Health Care | 0.25% | $3.70M |
| Phibro Animal Health Corp. Cl A | PAHC | Health Care | 0.20% | $3.07M |
| Ionis Pharmaceuticals, Inc. | IONS | Health Care | 0.20% | $3.07M |
| Edgewise Therapeutics, Inc. | EWTX | Health Care | 0.19% | $2.86M |
| Fidelity Cash Central Fund | — | Funds & ETFs | 0.17% | $2.59M |
| Paragon Biosciences Emalex Capital, Inc. Ser C Pc Pp | — | Health Care | 0.15% | $2.20M |
| Castle Creek Biosciences, Inc. Ser D-1 Pc Pp | — | Health Care | 0.09% | $1.41M |
| Evozyne, Inc. Cpik 6% 09/13/2028 P/p | — | Health Care | 0.08% | $1.22M |
| Evozyne, Inc. Ser B Pc Pp | — | Health Care | 0.06% | $948.20K |
| Paragon Biosciences Emalex Capital, Inc. Ser D-2 Pc Pp | — | Health Care | 0.02% | $310.86K |
| Paragon Biosciences Emalex Capital, Inc. Ser D-1 Pc Pp | — | Health Care | 0.01% | $220.96K |
| Kailera Therapeutics, Inc. | KLRA | Health Care | 0.01% | $206.46K |
| Agomab Therapeutics SA ADR | AGMB | Health Care | 0.01% | $102.38K |
| Evozyne, Inc. Ser A Pc Pp | — | Health Care | 0.01% | $96.23K |
| Paragon Biosciences Emalex Capital, Inc. Ser D-3 Pc Pp | — | Health Care | 0.00% | $63.36K |
| Castle Creek Biosciences, Inc. Ser C Pc Perp Pp | — | Health Care | 0.00% | $50.86K |
| Myos Corp. Restricted | — | Consumer Staples | 0.00% | $50.00K |
| Castle Creek Biosciences, Inc. Ser D-2 Pc Pp | — | Health Care | 0.00% | $16.97K |
| Medavail Holdings, Inc. Pipe | — | Health Care | 0.00% | $0 |
FPHAX Sector Allocation
Select Pharmaceuticals Portfolio holdings grouped by sector, by share of the portfolio's market value.
| Sector | Weight | Holdings |
|---|---|---|
| Health Care | 97.0% | 53 |
| Funds & ETFs | 2.6% | 2 |
| Consumer Staples | 0.4% | 2 |
FPHAX Country Allocation
Where Select Pharmaceuticals Portfolio's holdings are domiciled, by percentage of net assets (largest 12).
| Country | % of net assets |
|---|---|
| United States | 64.8% |
| United Kingdom | 15.1% |
| Belgium | 5.3% |
| Switzerland | 4.5% |
| Cayman Islands | 4.5% |
| Ireland | 4.1% |
| Canada | 1.1% |
| Germany | 1.0% |
| Sweden | 0.5% |
| Brazil | 0.4% |
| Netherlands | 0.3% |
| Denmark | 0.3% |
FPHAX Portfolio Allocation
Asset-class allocation of Select Pharmaceuticals Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.4% |
| Cash & Equivalents | 2.6% |
| Fixed Income | 0.1% |
FPHAX Debt Constituents
Largest debt holdings of Select Pharmaceuticals Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Evozyne, Inc. | 0.08% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.